Why the study?
Does the angiotensin receptor (AT2R) agonist C21 prevent cognitive decline in aged animals after permanent stroke?
Does the angiotensin receptor (AT2R) agonist C21 prevent cognitive decline in aged animals after permanent stroke?
Oral administration of the AT2R agonist C21 starting 24 hours post-stroke prevents the development of cognitive impairment in aged animal models.
Supports AT2R agonism for PSCI prevention in aged animal models; hypothesis-generating and requires human trials before clinical consideration.
Post stroke cognitive impairment (PSCI) is an understudied, long-term complication of stroke, impacting nearly 30-40% of all stroke survivors. No cure is available once the cognitive deterioration manifests. To our knowledge, this is the first study to investigate the long-term effects of C21 treatment on the development of PSCI in aged animals. Treatments with C21 or vehicle were administered orally, 24 h post-stroke, and continued for 30 days. Outcome measures for sensorimotor and cognitive function were performed using a sequence of tests, all blindly conducted and assessed at baseline as well as at different time points post-stroke. Our findings demonstrate that the angiotensin receptor (AT2R) agonist C21 effectively prevents the development of PSCI in aged animals.
No takes yet. Share an insight, caveat, or question.
Ahmed et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: